Towards A Chlamydia Vaccine For Males: The Key Role Of Mucosal IgA
Funder
National Health and Medical Research Council
Funding Amount
$418,978.00
Summary
Genital Chlamydia infections are the most common sexually transmitted infection in Australia with annual health costs of 90-160 million dollars. Infection rates in 15-29 olds are increasing at 15-20% per year in both females and males. Antibiotics are currently the treatment of choice, however antibiotic resistance is increasing and most infections are asymptomatic and not treated in the absence of screening programs. This project aims to develop a Chlamydia vaccine tailored to protect males .